CellGate Inc., of Sunnyvale, Calif., appointed Gary Visor vice president, pharmaceutical operations.

Cellomics Inc., of Pittsburgh, added James Sharp, Norbert Gorny, Ulrich Simon, Jonathan Fleming and Barclay Phillips to its board. CEO Lansing Taylor was elected chairman.

Cephalon Inc., of West Chester, Pa., appointed Joseph Turi vice president, worldwide drug development.

Cerus Corp., of Concord, Calif., appointed Elizabeth Tillson vice president, regulatory affairs and quality.

Chromos Molecular Systems Inc., of Burnaby, British Columbia, appointed Harry Ledebur vice president, research and development.

CITA Biomedical Inc., of Beverly Hills, Calif., named John Peters chief financial officer.

Commonwealth Biotechnologies Inc., of Richmond, Va., added Charles Waldridge as senior vice president, strategic business initiatives.

Corixa Corp., of Seattle, appointed Wayne Gombotz as vice president, process sciences and pharmaceutical development.

Enanta Pharmaceuticals Inc., of Watertown, Mass., named Yujiro Hata vice president, business development.

Endovasc Ltd., of Montgomery, Texas, added Robert Horn as a managing director, finances.

Favrille Inc., of San Diego, appointed John Gutheil vice president, medical research, and Alice Wei vice president, regulatory affairs and quality.

Genta Inc., of Berkeley Heights, N.J., appointed William Keane vice president and chief financial officer.

GTC Biotherapeutics Inc., of Framingham, Mass., appointed Marvin Miller to its board.

HelixSphere Technologies Inc., of Calgary, Alberta, appointed Michael Sheppard to its board.

High Throughput Genomics Inc., of Tucson, Ariz., appointed Kirk Collamer vice president and chief financial officer.

Incyte Genomics Inc., of Palo Alto, Calif., added Jason Rubin as executive vice president of corporate affairs.

Inflazyme Pharmaceuticals Ltd., of Richmond, British Columbia, appointed Graham Wilson to its board.

Inhale Therapeutic Systems Inc., of San Carlos, Calif., appointed Chris Kuebler and Michael Brown to its board.

Keryx Biopharmaceuticals Inc., of Cambridge, Mass., appointed Francis Fildes to its board.

La Jolla Pharmaceutical Co., of San Diego, appointed David Duncan chief financial officer and Karen Church vice president of regulatory affairs. It also promoted Matthew Linnik to chief scientific officer and executive vice president of research and William Welch to vice president of sales and marketing.

Large Scale Biology Corp., of Vacaville, Calif., added Christine Arakelian as senior director, business development.

Lipid Sciences Inc., of Pleasanton, Calif., elected Bryan Brewer to its board.

MDS Proteomics A/S, of Odense, Denmark, added Thodoros Topaloglou as vice president, bioinformatics.

Nereus Pharmaceuticals Inc., of San Diego, appointed Deborah Mosca vice president, research.

NPS Pharmaceuticals Inc., of Salt Lake City, appointed Stephen Parrish vice president, manufacturing.